DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,610,287 B2 Holm Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,610,287 B2 Holm Et Al USOO961 0287B2 (12) United States Patent (10) Patent No.: US 9,610,287 B2 Holm et al. (45) Date of Patent: Apr. 4, 2017 (54) METHOD OF ADMINISTRATION OF (56) References Cited 4-((1R,3S)-6-CHLORO-3-PHENYL-INDAN 1-YL)-1.2.2-TRIMETHYL-PIPERAZINE AND U.S. PATENT DOCUMENTS THE SALTS THEREOF IN THE TREATMENT 7,767,683 B2 8/2010 Lopez de Diego et al. OF SCHIZOPHRENA 8,076.342 B2 12/2011 Lopez de Diego et al. 8,227,607 B2 7/2012 de Diego et al. (75) Inventors: René Holm, Jyllinge (DK); Lone Bruun, Solred Strand (DK) FOREIGN PATENT DOCUMENTS RU 2006140962 A 11 2006 (73) Assignee: H. Lundbeck A/S, Valby (DK) WO 2005102342 A1 11 2005 WO 200701 1955 A2 1, 2007 (*) Notice: Subject to any disclaimer, the term of this WO 2009 135495 A1 11, 2009 patent is extended or adjusted under 35 WO 2010/037398 A1 4/2010 WO 2010O37398 A1 4/2010 U.S.C. 154(b) by 57 days. WO 2010149727 A2 6, 2010 (21) Appl. No.: 14/126,499 OTHER PUBLICATIONS (22) PCT Fed: Jun. 20, 2012 International Search Report and Written Opinion issued Jul. 26. 2012 in International Application No. PCT/EP2012/061779. (86) PCT No.: PCT/EP2012/061779 Anonymous, Mar. 23, 2010, "Zicronapine”. New Drugs Online, XP002680825, Retrieved from the Internet: URL: http://www.ukmi. S 371 (c)(1), nhs.uk/applications/ndo/record view open. (2), (4) Date: Mar. 14, 2014 asp?newDrugID=5028 retrieved on Jul. 26, 2012). Clozapine Augmentation Article, Graylands Hospital Drug Bulletin (87) PCT Pub. No.: WO2012/175531 2004, vol. 12 No. 1, March ISSN 123-1251, Claramont, WA, 6 pageS. PCT Pub. Date: Dec. 27, 2012 Kito et al., “The Rehospitalization-reducing Effect of Supporting Self-administration According to Individual Cognitive Function of (65) Prior Publication Data Patients with Schizophrenia', Nippon Byolin Yakuzaishikai, vol. 46, No. 8, pp. 1114-1117 (2010). US 2014/O194409 A1 Jul. 10, 2014 New Pharmacology, 3rd revised edition, pp. 20-21, 268-278. Goffet al., “Once-weekly D-cycloserine effects on negative symp toms and cognition in Schizophrenia: An exploratory study’. Related U.S. Application Data Schizophrenia Research, vol. 106, pp. 320-327 (2008). Kane et al., “A Double-Blind, Randomized Study Comparing the (60) Provisional application No. 61/498,653, filed on Jun. Efficacy and Safety of Sertindole and Risperidone in Patients with 20, 2011. Treatment-Resistant Schizophrenia'. J. Clin. Psychiatry, vol. 72, No. 2, pp. 194-204 (2011). (30) Foreign Application Priority Data Manual of Diagnosis and Therapy, vol. II, Editor in Chief, Robert Berkow, D.M., pp. 57-65 (1997). Jun. 20, 2011 (DK) ................................. 2011 OO465 “The clinical phase III programme commenced on Zicronapine'. Corporate Release No. 423, 3 pages, (2011). (51) Int. C. Chemistry Database, Compound Summary for CID 11465618 A6 IK 3/495 Zicronapine. (2006.01) New Drugs Online XP-002680825. Online Report for Zicronapine. A 6LX 3/553 (2006.01) Japanese Office Action dated Dec. 20, 2016 issued in corresponding A6 IK 3L/4545 (2006.01) Japanese application. A6 IK3I/554 (2006.01) Partial English language translation of New General Pharmaceutics, A6 IK 3/496 (2006.01) Revised Third Edition, pp. 262-267 (1987). A6 IK 3L/455 (2006.01) New General Pharmaceutics, Revised Third Edition, pp. 262-267 A6 IK 3L/454 (2006.01) (1987). A 6LX 3/57 (2006.01) A 6LX 3/59 (2006.01) Primary Examiner — Sarah Pihonak (52) U.S. C. Assistant Examiner — Jason A Deck CPC .......... A6 IK3I/495 (2013.01); A61K 31/454 (74) Attorney, Agent, or Firm — Morgan, Lewis & (2013.01); A61K 31/4515 (2013.01); A61 K Bockius, LLP 31/4545 (2013.01); A61K 31/496 (2013.01); A6 IK3I/517 (2013.01); A61K 3 1/519 (57) ABSTRACT (2013.01); A61 K3I/554 (2013.01); A61 K The present invention relates to 4-((1R,3S)-6-chloro-3-phe 3I/5513 (2013.01) nyl-indan-1-yl)-1.2.2-trimethyl-piperazine and the salts (58) Field of Classification Search thereof with activity at dopamine D and D receptors as CPC .............. A61K 31/495; A61K 31/4515; A61 K well as the serotonin 5HT receptor for the treatment of 31/454: A61K 31/4545; A61K 31/496; diseases in the central nervous system in a once weekly A61K 3 1/517: A61K 3 1/519: A61 K dosing regime. 31/5513; A61K 31/554 See application file for complete search history. 7 Claims, 1 Drawing Sheet U.S. Patent Apr. 4, 2017 US 9,610,287 B2 Panel 1 Study Design Zicronapine 10 mg/day H - - - - Zicronapine 10 mg/day Previous treatment dow- ask tapered 1 week Zicronapine 45 mg Once-Weekly No--- dosing SCreenin Oper-label Oeriod DOuble-blind treatment Oeriod Safety follow-up 2 weeks My 3 weeks M 5 weeks ah 8 weeks Baseline Randomisation Completion US 9,610,287 B2 1. 2 METHOD OF ADMINISTRATION OF vitro. The compound is also described as a potent 5-HT 4-((1R,3S)-6-CHLORO-3-PHENYL-INDAN antagonist. It is also mentioned that the compound does not 1-YL)-1.2.2-TRIMETHYL-PIPERAZINE AND induce catalepsy in rats. THE SALTS THEREOF IN THE TREATMENT The aetiology of schizophrenia is not known, but the OF SCHIZOPHRENA dopamine hypothesis of Schizophrenia formulated in the early 1960s, has provided a theoretical framework for under CROSS-REFERENCE TO RELATED standing the biological mechanisms underlying this disorder APPLICATIONS (Carlsson, Am. J. Psychiatry 1978, 135, 164-173). In its simplest form, the dopamine hypothesis states that schizo The present application is a National Stage Application 10 phrenia is associated with a hyperdopaminergic state, a which claims priority of International Application No. PCT/ notion which is supported by the fact that all antipsychotic EP12/061779, filed Jun. 20, 2012, which claims priority of drugs on the market today exert some dopamine D receptor U.S. Provisional Application No. 61/498,653, filed Jun. 20, antagonism (Seeman Science and Medicine 1995, 2, 28-37). 2011 and Danish Application No. PA201100465, filed Jun. However, whereas it is generally accepted that antagonism 20, 2011. Each of these applications is hereby incorporated 15 of dopamine D receptors in the limbic regions of the brain by reference in its entirety. plays a key role in the treatment of positive symptoms of Schizophrenia, the blockade of D receptors in striatal FIELD OF THE INVENTION regions of the brain causes extrapyramidal symptoms (EPS). As described in EP 638 073 a profile of mixed dopamine The present invention relates to 4-((1R,3S)-6-chloro-3- D/D receptor inhibition has been observed with some phenyl-indan-1-yl)-1.2.2-trimethyl-piperazine and the salts so-called "atypical antipsychotic compounds, in particular thereof with activity at dopamine D and D receptors as with clozapine (8-chloro-11-(4-methylpiperazin-1-yl)-5H well as the serotonin 5HT, receptor for the treatment of dibenzob.e. 1.4 diazepine), used in treatment of Schizo diseases in the central nervous system in a once weekly phrenic patients. dosing regime. 25 Further, selective Dantagonists have been connected to treatment of sleep disorders and alcohol abuse (D. N. Eder, BACKGROUND OF THE INVENTION Current Opinion in Investigational Drugs, 2002 3(2):284 288). 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1.2.2-trim Dopamine may also play an important role in the aetiol ethyl-piperazine and the salts thereof, pharmaceutical com 30 ogy of affective disorders (P. Willner, Brain. Res. Rev. 1983, positions containing these salts and the medical use thereof, 6, 211-224, 225-236 and 237-246; Bogese et al., J. Med. including treatment of schizophrenia or other diseases Chem., 1985, 28, 1817-1828). involving psychotic symptoms, is disclosed in WO2005/ In EP 638 073 is described how compounds having 0.16900. 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1.2.2- affinity for 5-HT, receptors, in particular 5-HT, receptor trimethyl-piperazine is hereinafter referred to as Compound 35 antagonists, have been suggested for treatment of different (I) diseases, such as Schizophrenia including the negative symptoms in Schizophrenic patients, depression, anxiety, sleep disturbance, migraine attacks and neuroleptic-induced (I) parkinsonism. 5-HT2 receptor antagonism has also been 40 Suggested to reduce the incidence of extrapyramidal side effects induced by classical neuroleptics (Balsara et al. Psychopharmacology 1979, 62, 67-69). Psychotic patients, and in particular schizophrenic patients, are often unwilling or unable to take their medi 45 cation regularly; several studies have shown that a less frequent dosing results in higher degree of compliance and thus eventually better treatment of the patients. Therefore there is an unmet need for long acting preparations of antipsychotic medicine. In particular there is a need for long 50 acting preparations of antipsychotic medicine in non-inva sive form that represent an alternative to intra muscular depot formulations in order to make change in dosing regime, frequency of medication or type of medication, more flexible. Compound (I) is also known as Zicronapine. 55 EP 638 073 covers a group of trans isomers of 3-aryl-1- SUMMARY OF THE INVENTION (1-piperazinyl)indanes Substituted in the 2- and/or 3-posi tion of the piperazine ring. The compounds are described as The inventors of the present invention have Surprisingly having high affinity for dopamine D and D receptors and found that the elimination half life of Compound (I) in the 5-HT, receptor and are suggested to be useful for 60 human is about 150 hours. The long elimination half life in treatment of several diseases in the central nervous system, combination with affinity for both dopamine D1 and D2 including Schizophrenia.
Load more

Recommended publications
  • (Schizophrenia) – Forecast and Market Analysis to 2022
    REFERENCE CODE GDHC367DFR | PUBLICATION DATE FEBRUARY 2014 BREXPIPRAZOLE (SCHIZOPHRENIA) – FORECAST AND MARKET ANALYSIS TO 2022 BREXPIPRAZOLE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Table below provides a summary of the key May have an effect on negative symptoms. metrics for Brexpiprazole in the seven major Otsuka has a strong presence in the pharmaceutical markets during the forecast period schizophrenia drug market. upto 2022. Conversely, the major barriers for the growth of Brexpiprazole : Key Metrics in the Seven Major Brexpiprazole in the schizophrenia market include: Pharmaceutical Markets, 2012–2022 Key Events (2012-2022) Level of Impact Higher cost of therapy compared to older Anticipated launch of Brexpiprazole in ↑↑↑ medications. US(2015) Anticipated launch of Brexpiprazole in ↑↑ Requires daily oral dosing. Japan (2016) 2022 Market Sales The figure below illustrates Brexpiprazole sales in US $1,648.9m the 7MM by region during the forecast period. 5EU $28.4m Japan $105.8m Sales for Brexpiprazole by Region, 2022 7MM $1,783.1m 5.9% 1.6% 2022 Source: GlobalData. Total : $1,783.1m 7MM = US, France, Germany, Italy, Spain, UK, Japan; 5EU = France, Germany, Italy, Spain, UK US Sales of Brexpiprazole in Global Schizophrenia 5EU Market, 2022 Japan Brexpiprazole sales are expected to increase from $176.2 million upon launch in 2015 to $1,783.1 92.5% million in 2022. Source: GlobalData. Major growth drivers for Brexpiprazole in the Schizophrenia market over the forecast period include: Structurally similar to Otsuka’s Abilify, the current market leader in the schizophrenia drug market. Improved tolerability and similar efficacy to Abilify demonstrated in clinical trials.
    [Show full text]
  • FDA Provides New Guidance on Antipsychotic Usage During
    Clinical News Peter F. Buckley, MD Editor-in-Chief FDA Provides New Guidance on impact of prolonged exposure to antipsychotic medications Antipsychotic Usage during upon total brain volume, as well as both gray matter and Pregnancy caudate-putamen volumes. Modest volumetric reductions were observed. There appeared to be a dose effect of antipsy- The U.S. Food and Drug Administration (FDA), tak- chotics as well. Although the effects were not independent ing stock of all available and new pharmacoepidemiological of other factors that are known to influence potential brain information on antipsychotic medication use, has provided changes—namely, duration of follow-up, illness severity, and updated guidance on prescribing antipsychotics during and comorbid substance abuse—the effect of medications per- immediately after pregnancy. Firstly, the FDA report affirms sisted even when these other influences were taken into ac- the long-held clinical message that untreated psychosis in count statistically. This is a noteworthy observation. the expectant mother is associated with (far) greater risk While the results are still open to other interpretations, than the risks associated with continued use of antipsychot- the observations for this study are sobering. They are also ics. Nevertheless, the report cautions about risks of antipsy- in line with earlier preclinical studies from the University chotic medications for extrapyramidal side effects (EPS) and of Pittsburgh that have demonstrated potential neurotoxic withdrawal side effects in the newborn. The report cites out- effects of antipsychotic medication upon selective neurons. comes for 69 instances of EPS and withdrawal side effects Nevertheless, the “jury is still out” on this contentious top- that were reported to the FDA up until the fall of 2008.
    [Show full text]
  • WO 2016/123576 Al 4 August 2016 (04.08.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/123576 Al 4 August 2016 (04.08.2016) P O P C T (51) International Patent Classification: Unit L, Baltimore, Maryland 21209 (US). WEINBER¬ A61K 31/535 (2006.01) GER, Daniel; 3116 Davenport St. NW, Washington, Dis trict of Columbia 20008-2244 (US). (21) International Application Number: PCT/US2016/015832 (74) Agent: KELLY, Bryte; King & Spalding LLP, 1185 Av enue of the Americas, New York, New York 10036 (US). (22) International Filing Date: 29 January 2016 (29.01 .2016) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Language: English Filing AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 62/109,954 30 January 2015 (30.01.2015) US KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant: LIEBER INSTITUTE FOR BRAIN DE¬ MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, VELOPMENT [US/US]; 855 North Wolfe Street, Suite PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 300, 3rd Floor, Baltimore, Maryland 21205 (US). SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Davey KJ Phd 2013.Pdf
    UCC Library and UCC researchers have made this item openly available. Please let us know how this has helped you. Thanks! Title The gut microbiota as a contributing factor to antipsychotic-induced weight gain and metabolic dysfunction Author(s) Davey, Kieran Publication date 2013 Original citation Davey, K. 2013. The gut microbiota as a contributing factor to antipsychotic-induced weight gain and metabolic dysfunction. PhD Thesis, University College Cork. Type of publication Doctoral thesis Rights © 2013. Kieran Davey http://creativecommons.org/licenses/by-nc-nd/3.0/ Embargo information Restricted to everyone for one year Item downloaded http://hdl.handle.net/10468/1243 from Downloaded on 2021-10-09T20:00:22Z Ollscoil na hEireann National Unversity Ireland Colaiste na hOllscoile, Corcaigh University College Cork School of Pharmacy The Gut Microbiota as a Contributing Factor to Antipsychotic-Induced Weight Gain and Metabolic Dysfunction Thesis presented by Kieran J. Davey under the supervision of Prof. John F. Cryan Prof. Timothy G. Dinan Dr Siobhain M. O’Mahony for the degree of Doctor of Philosophy Head of School: CatrionaO’Driscoll Contents Declaration ........................................................................................................................................... vii Acknowledgements .......................................................................................................................... viii Publications and presentations .....................................................................................................
    [Show full text]
  • Achat Viagra Puissant ### Ablation Prostate Et Viagra >>> Kvadridze.Github.Io
    Viagra est indiquée pour le traitement de la dysfonction érectile masculine. >>> ORDER NOW <<< Achat viagra puissant Tags: ordonnance de viagra combien de temps dur viagra comment peut on se procurer du viagra efficacité viagra générique un site fiable pour acheter du viagra le viagra sur ordonnance danger dacheter du viagra sur internet prix cachet viagra combien coute le viagra au maroc le rôle de viagra peut acheter du viagra sans ordonnance quesque cest viagra composition de viagra acheter viagra paris sans ordonnance comment se procurer viagra sans ordonnance comment reconnaitre le faux viagra quand faut il prendre viagra comment acheter du viagra au quebec lancement du viagra quest ce que cest le viagra viagra pfizer mode demploi les conséquences du viagra edex plus viagra comment prendre de viagra forum viagra pas cher commande de viagra en ligne meme effet que viagra prendre la moitié dun viagra experience viagra femme A vaginal ring can slip out of the vagina. In the event of overdosage, general symptomatic and achat viagra puissant measures are indicated as required Resistance to azithromycin may be inherent or acquired. Comments: Take one pill a day. Ca 20 minuter senare börjar mina kollegor droppa in i ordningen: Susanne, Britt, Emma, Nina, Gunnel, Eva och sist Barbro. Epidemiologic investigations of this outbreak demonstrated that individuals in close contact with the index case or with exposure to poultry were at risk of being infected. 25 mg pour femme viagra cherche 2 weeks or until I "felt" like I could go lower. It might take a while to adapt to it, since it will lower your blood pressure.
    [Show full text]
  • Terminology Drug Development
    P. de Boer 20-3-2013 Drug Development 1. Drug development is for a well-accepted and New Developments in the demarcated indication that will become part Pharmacological Therapy of of the product label (rather than for a symptom – family of symptoms); Schizophrenia 2. Symptoms may overlap between disease Peter de Boer, PhD categories. It is acceptable to develop Senior Director Experimental Medicine multiple indications but it is generally not Janssen Research and Development acceptable to develop symptom-specific therapies. 3/8/2013 Psychosis Cluster 4 This presentation may contain off-label information or data on investigational compounds. Please always refer to the full product information before prescribing any medicine. Section 1 Views and opinions expressed in this presentation represent those of the presenter and are not necessarily the company. WHY CATEGORIES RATHER THAN DIMENSIONS? 3/8/2013 Psychosis Cluster 2 3/8/2013 Psychosis Cluster 5 Schizophrenia as a disorder of Terminology Frequency cognition (1) Category: An ICD-10/DSM-IV diagnosis (e.g., • Schizophrenia Normal schizophrenia, schizoaffective disorder, Morbid schizotypal personality disorder); Premorbid • Dimension: A symptom or symptom cluster that occurs throughout the population and that, if of sufficient intensity, may lead to a categorical diagnosis (e.g., aberrant sensory experiences); • Symptom: A characteristic sign (e.g., a delusion, IQ Test Score avolition); Impaired Normal High Functioning • Target: A biological process affected by a drug. 3/8/2013 Psychosis Cluster 3 3/8/2013 Psychosis Cluster 6 Nascholing Psychosen 14-15 maart 2013 1 P. de Boer 20-3-2013 Schizophrenia as a disorder of Psychosis: Dimension/Category (2) Frequency cognition (2) Intensity Schizophrenia Psychotic Experiences Schizophrenia Normal 1% Schizotypical Tx A 10% C Normal 1% Test Score 40% 49% Impaired B Normal High Functioning Not strictly continuous variables? 3/8/2013 Psychosis Cluster 7 3/8/2013 Psychosis Cluster 10 Schizophrenia as a disorder of Psychosis in dementia cognition - issues 1.
    [Show full text]
  • Current Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE
    Send Orders for Reprints to [email protected] 3385 Cur rent Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE ISSN: 1568-0266 eISSN: 1873-5294 Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Impact Factor: 2.9 The international Present and Future journal for in-depth reviews on Current Topics in Medicinal Chemistry BENTHAM SCIENCE Peng Li*, Gretchen L. Snyder and Kimberly E. Vanover Intra-Cellular Therapies Inc, 430 East 29th Street, Suite 900, New York, NY 10016, USA Abstract: Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approxi- mately 1% of the world’s population. This disease is associated with considerable morbidity placing a major financial burden on society. Antipsychotics have been the mainstay of the pharmacological treatment of schizophrenia for decades. The traditional typical and atypical antipsychotics demon- strate clinical efficacy in treating positive symptoms, such as hallucinations and delusions, while are A R T I C L E H I S T O R Y largely ineffective and may worsen negative symptoms, such as blunted affect and social withdrawal, as well as cognitive function. The inability to treat these latter symptoms may contribute to social Received: April 07, 2016 Revised: May 20, 2016 function impairment associated with schizophrenia. The dysfunction of multiple neurotransmitter Accepted: May 23, 2016 systems in schizophrenia suggests that drugs selectively targeting one neurotransmission pathway DOI: 10.2174/1568026616666160608 are unlikely to meet all the therapeutic needs of this heterogeneous disorder. Often, however, the un- 084834 intentional engagement of multiple pharmacological targets or even the excessive engagement of in- tended pharmacological targets can lead to undesired consequences and poor tolerability.
    [Show full text]
  • Annual Report 2011 3) the Calculation Is Based on a Share Denomination of DKK 5
    Financial highlights Group 2011 2010 2009 2008 2007 2011 2011 DKKm DKKm DKKm DKKm DKKm EURm1 USDm2 Revenue 16,007 14,765 13,747 11,572 11,171 2,148 2,987 Research and development costs 3,320 3,045 3,196 2,990 2,193 446 620 Operating profit before depreciation and amortisation (EBITDA) 4,628 4,393 3,728 3,418 3,611 621 864 Profit from operations (EBIT) 3,393 3,357 2,858 2,354 2,689 455 633 Net financials (96) (68) (192) (28) 65 (13) (18) Profit for the year 2,282 2,466 2,007 1,663 1,881 306 426 Total assets 20,534 18,005 17,127 12,526 12,230 2,762 3,574 Equity 12,776 11,122 8,803 7,511 7,089 1,719 2,224 Cash flows from operating and investing activities 929 2,462 (2,040) 2,193 1,610 125 173 Investments in property, plant and equipment, gross 419 383 258 229 474 56 73 % % % % % % % EBITDA margin 28.9 29.8 27.1 29.5 32.3 28.9 28.9 EBIT margin 21.2 22.7 20.8 20.3 24.1 21.2 21.2 Return on capital employed 25.3 27.6 28.0 30.0 34.6 25.3 25.3 Return on equity 19.1 24.8 24.6 22.8 27.3 19.1 19.1 Research and development ratio 20.7 20.6 23.2 25.8 19.6 20.7 20.7 Solvency ratio 62.2 61.8 51.4 60.0 58.0 62.2 62.2 Capital turnover 78.0 82.0 80.3 92.4 91.3 78.0 78.0 Effective tax rate 30.8 25.0 24.7 27.1 29.6 30.8 30.8 DKK DKK DKK DKK DKK EUR1 USD2 Earnings per share (EPS)3 11.63 12.57 10.24 8.45 9.18 1.56 2.17 Diluted earnings per share (DEPS)3 11.63 12.57 10.24 8.45 9.17 1.56 2.17 Proposed dividend per share3 3.49 3.77 3.07 2.30 2.56 0.47 0.65 Cash flow per share3 18.48 16.65 15.47 14.12 13.18 2.48 3.45 Net asset value per share3 65.14 56.71 44.89
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients
    This is a repository copy of Antipsychotics for treatment of delirium in hospitalised non-ICU patients. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/132847/ Version: Published Version Article: Burry, Lisa, Mehta, S.R., Perreault, M.M et al. (6 more authors) (2018) Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews. CD005594. ISSN 1469-493X https://doi.org/10.1002/14651858.CD005594.pub3 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Antipsychotics for treatment of delirium in hospitalised non- ICU patients (Review) Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews 2018, Issue 6.
    [Show full text]
  • Global Drug Forecast and Market Analysis to 2022
    REFERENCE CODE GDHC81PIDR | PUBLICATION DATE FEBRUARY 2014 SCHIZOPHRENIA – GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 SCHIZOPHRENIA - GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Schizophrenia: Key Metrics in the Seven Major The table above provides a summary of the key Pharmaceutical Markets, 2012–2022 metrics for schizophrenia in the seven major 2012 Epidemiology pharmaceutical markets during the forecast period Prevalent population 2.5 million from 2012–2022. Treated population 2.0 million 2012 Market Sales Schizophrenia Drug Sales by Region, 2012– US $5.2bn 2022 5EU $0.4bn Japan $0.7bn The combined sales of medications carrying an Total $6.3bn indication in schizophrenia were estimated at $6.3 Pipeline Assessment billion in 2012. By 2022, GlobalData projects these Number of drugs in Phase II–III 11 sales to grow to $7.9 billion, with a compound Number of first-in-class drugs 2 annual growth rate (CAGR) of 2.40% over the Peak-Year Promising Pipeline Candidates Sales course of the decade. These estimates cover the Brexpiprazole (Otsuka/Lundbeck) $1.8bn sales in the seven major markets (7MM) included Cariprazine (Forest/Gedeon Richter) $0.9bn in this report: the US, France, Germany, Italy, EVP-6124 (EnVivo/Mitsubishi Tanabe) $0.8bn Aripiprazole lauroxil (Alkermes) $0.7bn Spain, the UK, and Japan. We believe that the Invega Sustenna (Three-Month) $0.6bn following parameters will drive expansion in these Level of Key Events (2012–2022) markets: Impact Zyprexa (olanzapine) patent expiry in the ↓↓ Growing awareness of mental health 5EU in 2012 Seroquel (quetiapine) patent expiry in the US ↓↓ Enhanced community-level mental health care and 5EU in 2012 Geodon (ziprasidone) patent expiry in the US ↓ New product launches in 2012 Launch of Abilify Maintena (aripiprazole) in ↑↑↑ Increasing utilization of long-acting injectable the US in 2013 Abilify (aripiprazole) patent expiry in the US (LAI) antipsychotics ↓↓↓ and 5EU in 2015 2022 Market Sales US $6.1bn 5EU $0.4bn Japan $1.4bn 7MM $7.9bn Source: GlobalData.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]